Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryCRO

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1785722

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1785722

Antibody Contract Development and Manufacturing Organization

PUBLISHED:
PAGES: 276 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Antibody Contract Development and Manufacturing Organization Market to Reach US$68.3 Billion by 2030

The global market for Antibody Contract Development and Manufacturing Organization estimated at US$29.1 Billion in the year 2024, is expected to reach US$68.3 Billion by 2030, growing at a CAGR of 15.3% over the analysis period 2024-2030. Monoclonal Antibodies CDMO, one of the segments analyzed in the report, is expected to record a 16.9% CAGR and reach US$43.6 Billion by the end of the analysis period. Growth in the Polyclonal Antibodies CDMO segment is estimated at 14.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.6 Billion While China is Forecast to Grow at 14.3% CAGR

The Antibody Contract Development and Manufacturing Organization market in the U.S. is estimated at US$7.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2030 trailing a CAGR of 14.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.3% and 13.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.0% CAGR.

Global Antibody Contract Development and Manufacturing Organization (CDMO) Market - Key Trends & Drivers Summarized

How Are Antibody CDMOs Revolutionizing Biologic Drug Development?

The antibody contract development and manufacturing organization (CDMO) market is undergoing a significant transformation, spurred by advancements in biologic drug research, increasing regulatory complexities, and a growing demand for therapeutic antibodies. The role of CDMOs has expanded beyond mere manufacturing; these organizations now offer integrated services encompassing early-stage development, process optimization, clinical trial production, and large-scale commercial manufacturing. This expansion is largely driven by biopharmaceutical companies that seek to streamline costs and accelerate time-to-market for their innovative monoclonal and polyclonal antibody-based therapies. Notably, the rise in personalized medicine and immunotherapy has further propelled the demand for high-quality, customizable antibody production. With pharmaceutical companies increasingly relying on external expertise, CDMOs are leveraging advanced bioprocessing technologies, including single-use bioreactors, continuous manufacturing, and artificial intelligence-driven optimization techniques, to enhance efficiency and scalability.

Why Is the Market Experiencing a Surge in Demand?

The antibody CDMO market is experiencing a surge in demand primarily due to the rising prevalence of chronic and infectious diseases, which has driven the development of targeted biologic therapies. With an increasing number of pharmaceutical firms shifting their focus toward biologics over small molecules, the need for specialized antibody development and manufacturing services has skyrocketed. Additionally, biosimilar competition is intensifying as patent expirations open doors for new players to enter the market, further driving the necessity for CDMOs that can efficiently produce high-quality biosimilars. Geographically, North America and Europe remain dominant players in the sector, but emerging markets in Asia-Pacific, particularly China and India, are rapidly gaining traction due to lower operational costs and expanding biomanufacturing infrastructures. Furthermore, the evolving regulatory landscape is pushing CDMOs to adopt stringent compliance measures, ensuring adherence to Good Manufacturing Practices (GMP) and evolving FDA, EMA, and ICH guidelines. This adherence to rigorous standards is essential to securing contracts with leading biopharmaceutical firms, thereby fueling market growth.

How Is Innovation Reshaping Antibody CDMO Capabilities?

Technological advancements are playing a pivotal role in reshaping the antibody CDMO market, with automation, digital bioprocessing, and novel expression systems driving efficiency and cost-effectiveness. High-throughput screening, cell-line development using CRISPR gene editing, and mammalian cell expression systems, such as CHO (Chinese Hamster Ovary) and HEK293 cells, have revolutionized antibody production processes. Additionally, the integration of digital twin technology-allowing for real-time process simulation and optimization-has significantly enhanced predictive capabilities, reducing batch failures and improving yields. The adoption of modular and flexible facilities has further enabled CDMOs to quickly adapt to varying production demands, ensuring rapid response to emerging market needs, such as pandemic-driven vaccine and therapeutic antibody production. Moreover, the growing trend of strategic partnerships and acquisitions among CDMOs and biopharma companies is fostering enhanced innovation and service diversification, allowing firms to offer end-to-end solutions from cell line development to fill-finish operations.

What Is Fueling the Growth of the Antibody CDMO Market?

The growth in the antibody CDMO market is driven by several factors, including the rising adoption of biologics and biosimilars, increasing outsourcing trends among pharmaceutical and biotechnology companies, and advancements in bioprocessing technologies. The shift toward personalized medicine and targeted therapies has created a significant demand for specialized antibody production services that cater to niche indications, such as oncology, autoimmune diseases, and rare genetic disorders. Additionally, the rapid expansion of the cell and gene therapy market is fueling investments in innovative antibody manufacturing platforms. The increasing prevalence of chronic diseases, combined with an aging global population, has also led to heightened demand for monoclonal antibody-based treatments, further propelling the need for scalable and cost-effective CDMO solutions. Moreover, regulatory support for faster drug approvals and breakthrough therapy designations is enabling antibody manufacturers to expedite clinical development timelines, thus intensifying the reliance on CDMOs. The rising need for cost-effective biomanufacturing solutions, particularly in emerging economies, and the integration of artificial intelligence and machine learning in process development are expected to further bolster the market’s expansion in the coming years. With ongoing innovations and strategic industry collaborations, the antibody CDMO market is set to experience robust growth, positioning itself as a crucial pillar in the evolving biopharmaceutical landscape.

SCOPE OF STUDY:

The report analyzes the Antibody Contract Development and Manufacturing Organization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO, Other Product Types); Source Type (Mammalian CDMO, Microbial CDMO); Application (Oncology Application, Neurology Application, Cardiology Application, Infectious Diseases Application, Immune-related Disorders Application, Other Applications); End-Use (Biopharma Companies End-Use, Research Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 39 Featured) -

  • AbbVie Contract Manufacturing
  • AGC Biologics
  • Boehringer Ingelheim International GmbH
  • Catalent Biologics
  • Charles River Laboratories
  • FUJIFILM Holdings America Corporation
  • Lonza Group AG
  • mAbxience
  • ProBioGen AG
  • Rentschler Biopharma SE
  • Samsung BioLogics Co., Ltd.
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP29178

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Antibody Contract Development and Manufacturing Organization - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Monoclonal Antibodies in Therapeutics Driving CDMO Growth
    • Expansion of Biopharmaceutical Outsourcing Trends Boosting CDMO Demand
    • Increasing Focus on Flexible Manufacturing Solutions for Rapid Scale-Up
    • Advancements in Single-Use Bioprocessing Technologies for Cost Efficiency
    • Growth in Personalized Medicine and Antibody-Based Targeted Therapies
    • Surge in Demand for Biosimilar Antibody Production and CDMO Partnerships
    • Expansion of Cell Line Development and High-Yield Expression Systems
    • Growing Adoption of AI and Machine Learning for Antibody Development Optimization
    • Increasing Strategic Collaborations Between Pharma Companies and CDMOs
    • Rise in Demand for Fully Integrated End-to-End CDMO Services
    • Expansion of Biologics CDMO Capabilities for Novel Antibody Modalities
    • Increasing Focus on Sustainable Biomanufacturing and Green Chemistry Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibody Contract Development and Manufacturing Organization Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibody Contract Development and Manufacturing Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monoclonal Antibodies CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monoclonal Antibodies CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monoclonal Antibodies CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polyclonal Antibodies CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polyclonal Antibodies CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polyclonal Antibodies CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immune-related Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immune-related Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immune-related Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cardiology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cardiology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Research Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Mammalian CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Mammalian CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Mammalian CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Microbial CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Microbial CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Microbial CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibody Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibody Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • CHINA
    • Antibody Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibody Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Antibody Contract Development and Manufacturing Organization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibody Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibody Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibody Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibody Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 182: Rest of World Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of World Historic Review for Antibody Contract Development and Manufacturing Organization by Product Type - Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of World 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies CDMO, Polyclonal Antibodies CDMO and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of World Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of World Historic Review for Antibody Contract Development and Manufacturing Organization by Application - Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of World 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Immune-related Disorders Application, Other Applications, Oncology Application, Neurology Application, Cardiology Application and Infectious Diseases Application for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of World Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of World Historic Review for Antibody Contract Development and Manufacturing Organization by End-Use - Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of World 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of World Recent Past, Current & Future Analysis for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of World Historic Review for Antibody Contract Development and Manufacturing Organization by Source Type - Mammalian CDMO and Microbial CDMO Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of World 15-Year Perspective for Antibody Contract Development and Manufacturing Organization by Source Type - Percentage Breakdown of Value Sales for Mammalian CDMO and Microbial CDMO for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!